DOTAREM® (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.
Dotarem® is a macrocyclic-structured gadolinium-based MRI contrast agent. Launched in France in 1989, Dotarem® is currently marketed in more than 70 countries.
Dotarem® combines optimal performance and excellent safety. In a large surveillance study with more 84,000 examinations, Dotarem demonstrated optimal efficacy in clinical practice.1 Dotarem has also proved its safety profile and is classified under the low risk group by Guidelines from main Health Authorities/Scientific societies: EMA, ESUR, FDA, American College of Radiology, Danish Health and Medicine Authority.